Journal: Frontiers in Pharmacology

Article Title: Very strong correlations of metoprolol- and solanidine-derived metabolic ratios in a real-world cohort with a stable metoprolol drug regimen

doi: 10.3389/fphar.2026.1812007

Figure Lengend Snippet: Linear regression of the lnMR (OH-metoprolol/metoprolol) in a subset of the ARIANA (“All-comer” Registry for ImmunocArdiology aNd cardiometabolic disease Aachen) study comprising patients with detected metoprolol levels (N = 47) with (A) lnMR (OH-solanidine/solanidine): r = 0.907 (95 CI: 0.838–0.948) and R 2 = 0.823 ( p < 0.0001), (B) lnMR (SSDA/solanidine): r = 0.946 (95 CI: 0.905–0.970) and R 2 = 0.896 ( p < 0.0001), and (C) CYP2D6 activity score as predicted by genotype: r = 0.500 (95 CI: 0.249–0.688) and R 2 = 0.250 ( p = 0.0003). Ln, natural logarithm; MR, metabolic ratio; SSDA, 3,4-secosolanidine-3,4-dioic acid; PM, genotype-predicted poor metabolizer; IM, genotype-predicted intermediate metabolizer; NM, genotype-predicted normal metabolizer; UM, genotype-predicted ultra-rapid metabolizer; XM, genotype-predicted indeterminate metabolizer; 95 CI, 95% confidence interval; CYP2D6, cytochrome P450 2D6.

Article Snippet: The following materials were used for the liquid chromatography–mass spectrometry (LC–MS) methods: solanidine (13264-1MG; Sigma), formic acid (84865.180, HiPerSolv; VWR Chemicals), metoprolol (HY-17503; MedChemExpress), α-OH-metoprolol (Cay28020-1; Biomol), methanol (ultra-gradient HPLC-grade; 8402; J.T.

Techniques: Activity Assay

Journal: Frontiers in Pharmacology

Article Title: Very strong correlations of metoprolol- and solanidine-derived metabolic ratios in a real-world cohort with a stable metoprolol drug regimen

doi: 10.3389/fphar.2026.1812007

Figure Lengend Snippet: Linear regression of metoprolol trough levels in a subset of the ARIANA (“All-comer” Registry for ImmunocArdiology aNd cardiometabolic disease Aachen) study comprising patients with detected metoprolol levels (N = 47) with (A) lnMR (OH-solanidine/solanidine): r = −0.513 (95 CI: −0.698 to −0.265) and R 2 = 0.263 ( p < 0.0002), (B) lnMR (SSDA/solanidine): r = −0.533 (95 CI: −0.711 to −0.291) and R 2 = 0.284 ( p = 0.0001), and (C) CYP2D6 activity score: r = −0.288 (95 CI: −0.531 to −0.001) and R 2 = 0.083 ( p = 0.499). Ln, natural logarithm; MR, metabolic ratio; SSDA, 3,4-secosolanidine 3,4-dioic acid; PM, genotype-predicted poor metabolizer; IM, genotype-predicted intermediate metabolizer; NM, genotype-predicted normal metabolizer; UM, genotype-predicted ultra-rapid metabolizer; XM, genotype-predicted indeterminate metabolizer; 95 CI, 95% confidence interval; CYP2D6, cytochrome P450 2D6.

Article Snippet: The following materials were used for the liquid chromatography–mass spectrometry (LC–MS) methods: solanidine (13264-1MG; Sigma), formic acid (84865.180, HiPerSolv; VWR Chemicals), metoprolol (HY-17503; MedChemExpress), α-OH-metoprolol (Cay28020-1; Biomol), methanol (ultra-gradient HPLC-grade; 8402; J.T.

Techniques: Activity Assay

Journal: Pharmaceutics

Article Title: Dose Accuracy and Content Uniformity of Low-Dose Metoprolol Tablets: 3D Printing Compared with Tablet Splitting in Hospital Pharmacy Setting

doi: 10.3390/pharmaceutics18050532

Figure Lengend Snippet: Study workflow for comparative evaluation of split versus 3D-printed metoprolol tartrate tablets. The workflow illustrates the two production pathways (manual splitting at Mayo Clinic and 3D printing via the CurifyLabs Compounding System Solution) and the analytical steps applied to each.

Article Snippet: Metoprolol tartrate assay and content uniformity analyses were performed using an HPLC system (Thermo ScientificTM Vanquish, Germering, Germany) with the ChromeleonTM (version 7.3.2) Chromatography Data System software.

Techniques:

Journal: Pharmaceutics

Article Title: Dose Accuracy and Content Uniformity of Low-Dose Metoprolol Tablets: 3D Printing Compared with Tablet Splitting in Hospital Pharmacy Setting

doi: 10.3390/pharmaceutics18050532

Figure Lengend Snippet: Mass variation of split commercial metoprolol tartrate tablets prepared as halves (12.5 mg) and quarters (6.25 mg) from Manufacturers A and B. Box plots show the distribution of tablet weights; horizontal lines indicate the median, boxes indicate interquartile range, and whiskers represent the full data range. Solid lines indicate the ±10% pharmacopeial acceptance limits. Raw individual-tablet mass data are provided in .

Article Snippet: Metoprolol tartrate assay and content uniformity analyses were performed using an HPLC system (Thermo ScientificTM Vanquish, Germering, Germany) with the ChromeleonTM (version 7.3.2) Chromatography Data System software.

Techniques:

Journal: Pharmaceutics

Article Title: Dose Accuracy and Content Uniformity of Low-Dose Metoprolol Tablets: 3D Printing Compared with Tablet Splitting in Hospital Pharmacy Setting

doi: 10.3390/pharmaceutics18050532

Figure Lengend Snippet: Quality evaluation of metoprolol tartrate tablets prepared by manual splitting and 3D printing: content uniformity and dissolution performance. ( A ) Content uniformity of split commercial tablets (Manufacturers A and B) at 6.25 mg and 12.5 mg. ( B ) Comparison of 6.25 mg content uniformity across manual splitting and 3D printing at Locations A–C. ( C ) Dissolution profiles of CurifyLabs-developed metoprolol tartrate gel tablet formulations (0.5%, 2%, and 3%) over 60 min. Raw individual API-content and mass data for all conditions shown in panels ( A , B ) are provided in .

Article Snippet: Metoprolol tartrate assay and content uniformity analyses were performed using an HPLC system (Thermo ScientificTM Vanquish, Germering, Germany) with the ChromeleonTM (version 7.3.2) Chromatography Data System software.

Techniques: Dissolution, Comparison